Protocol Ledger

NCT06722235 · Phase III · RECRUITING

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Interventional Phase III clinical trial protocol NCT06722235 sponsored by Takeda in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-27 Enrollment: 171 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06722235
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)171 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06722235
Protocol FieldVerified Registry Value
NCT IdentifierNCT06722235
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment171 participants (ESTIMATED)
Registered Start Date2025-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI